Skip to main content

Amjevita News

Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease

FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira

November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...

FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its...

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ankylosing Spondylitis, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Crohn's Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

Amjevita patient information at Drugs.com